drugset / Trial / NCT06168383
To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) .
RandomizedParallel-groupDouble-blindTreatment
Summary
A double-blind placebo controlled, randomized, Phase 2b study to evaluate the efficacy and safety of once-daily, oral administration of 80 or 160 mg HSK31679 versus matching placebo in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis.
Timeline
- Start
- 2024-01-05
- Primary completion
- 2025-12-12
- Completion
- 2026-01-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HSK31679 | Unknown | 80 mg | Oral |
| Subject | HSK31679 | Unknown | 160 mg | Oral |